Renee Ward

615 total citations
11 papers, 320 citations indexed

About

Renee Ward is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Renee Ward has authored 11 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Hematology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Renee Ward's work include Chronic Lymphocytic Leukemia Research (5 papers), Acute Myeloid Leukemia Research (4 papers) and Lymphoma Diagnosis and Treatment (3 papers). Renee Ward is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Acute Myeloid Leukemia Research (4 papers) and Lymphoma Diagnosis and Treatment (3 papers). Renee Ward collaborates with scholars based in United States, United Kingdom and Spain. Renee Ward's co-authors include Hagop M. Kantarjian, Steven D. Gore, Barry Skikne, Kyle J. MacBeth, Eric Laille, Guillermo Garcia‐Manero, Christopher R. Cogle, Tao Shi, Heidi Giordano and Elias Jabbour and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Renee Ward

11 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Renee Ward United States	8	196	164	125	84	53	11	320
Maho Ishikawa Japan	10	143 0.7×	88 0.5×	76 0.6×	42 0.5×	53 1.0×	40	277
Michael Heinsch Germany	8	267 1.4×	125 0.8×	88 0.7×	52 0.6×	48 0.9×	14	324
Patricia Kropf United States	9	138 0.7×	70 0.4×	193 1.5×	42 0.5×	59 1.1×	26	341
Sandra Bašić‐Kinda Croatia	11	102 0.5×	93 0.6×	96 0.8×	85 1.0×	87 1.6×	42	277
Marta Ubezio Italy	6	234 1.2×	181 1.1×	72 0.6×	34 0.4×	39 0.7×	10	325
Deborah Ruggeri Italy	8	281 1.4×	100 0.6×	172 1.4×	46 0.5×	53 1.0×	9	378
J. Maciejewski United States	7	259 1.3×	107 0.7×	180 1.4×	30 0.4×	30 0.6×	10	345
Paola Maria Cavigliano Italy	12	324 1.7×	136 0.8×	94 0.8×	51 0.6×	44 0.8×	27	384
Yannick Le Bris France	12	124 0.6×	108 0.7×	81 0.6×	90 1.1×	102 1.9×	45	337
Canan Alhan Netherlands	13	480 2.4×	203 1.2×	72 0.6×	66 0.8×	51 1.0×	32	520

Countries citing papers authored by Renee Ward

Since Specialization

Citations

This map shows the geographic impact of Renee Ward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Renee Ward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Renee Ward more than expected).

Fields of papers citing papers by Renee Ward

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Renee Ward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Renee Ward. The network helps show where Renee Ward may publish in the future.

Co-authorship network of co-authors of Renee Ward

This figure shows the co-authorship network connecting the top 25 collaborators of Renee Ward. A scholar is included among the top collaborators of Renee Ward based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Renee Ward. Renee Ward is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Allan, John N., Javier Pinilla‐Ibarz, Douglas E. Gladstone, et al.. (2021). Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 107(4). 984–987. 27 indexed citations

Stein, Eytan M., Marina Konopleva, Raymond Gilmour, et al.. (2020). A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress). Blood. 136(Supplement 1). 26–26. 9 indexed citations

Allan, John N., Krish Patel, Anthony R. Mato, et al.. (2019). Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies. Blood. 134(Supplement_1). 3041–3041. 26 indexed citations

Allan, John N., Keyur Patel, Anthony R. Mato, et al.. (2019). PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE‐ESCALATION AND COHORT‐EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B‐CELL MALIGNANCIES. HemaSphere. 3(S1). 520–520. 7 indexed citations

Allan, John N., William G. Wierda, Krish Patel, et al.. (2018). Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies. Blood. 132(Supplement 1). 3141–3141. 4 indexed citations

Weisdorf, Daniel J., Heather R. Millard, Mary M. Horowitz, et al.. (2016). Allogeneic transplantation for advanced acute myelogenous leukemia: The value of complete remission.. Journal of Clinical Oncology. 34(15_suppl). 7033–7033. 1 indexed citations

Ward, Renee, et al.. (2016). First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects. Blood. 128(22). 2032–2032. 28 indexed citations

Garcia‐Manero, Guillermo, Steven D. Gore, Christopher R. Cogle, et al.. (2011). Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Journal of Clinical Oncology. 29(18). 2521–2527. 193 indexed citations

Hennessy, Bryan T., et al.. (2009). Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib in HER2 Positive Breast Cancers: Role of ER and HER2 Reactivation.. Cancer Research. 69(24_Supplement). 708–708. 1 indexed citations

10.

Yang, A S, Virginia M. Klimek, S. M. Luger, et al.. (2007). Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Journal of Clinical Oncology. 25(18_suppl). 7062–7062. 12 indexed citations

11.

Heller, W., Danish Mazhar, Renee Ward, et al.. (2007). Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer. Oncology Reports. 17(1). 253–9. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact